Monterey Private Wealth Inc. Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Monterey Private Wealth Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 16.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,172 shares of the biopharmaceutical company’s stock after buying an additional 871 shares during the period. Monterey Private Wealth Inc.’s holdings in Pfizer were worth $324,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Piscataqua Savings Bank raised its position in shares of Pfizer by 0.8% in the 2nd quarter. Piscataqua Savings Bank now owns 25,820 shares of the biopharmaceutical company’s stock worth $1,354,000 after acquiring an additional 197 shares in the last quarter. Birinyi Associates Inc. raised its position in shares of Pfizer by 3.4% in the 1st quarter. Birinyi Associates Inc. now owns 6,000 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 200 shares in the last quarter. Curbstone Financial Management Corp raised its position in shares of Pfizer by 0.3% in the 1st quarter. Curbstone Financial Management Corp now owns 65,901 shares of the biopharmaceutical company’s stock worth $3,412,000 after acquiring an additional 200 shares in the last quarter. Douglass Winthrop Advisors LLC raised its position in shares of Pfizer by 0.3% in the 1st quarter. Douglass Winthrop Advisors LLC now owns 57,804 shares of the biopharmaceutical company’s stock worth $2,993,000 after acquiring an additional 200 shares in the last quarter. Finally, Oak Harbor Wealth Partners LLC raised its position in shares of Pfizer by 0.3% in the 1st quarter. Oak Harbor Wealth Partners LLC now owns 70,464 shares of the biopharmaceutical company’s stock worth $3,648,000 after acquiring an additional 203 shares in the last quarter. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Pfizer Trading Up 1.5 %

Shares of Pfizer stock opened at $44.57 on Friday. The firm has a market capitalization of $250.14 billion, a PE ratio of 8.72, a P/E/G ratio of 0.54 and a beta of 0.70. Pfizer Inc. has a twelve month low of $40.94 and a twelve month high of $61.71. The firm’s 50-day moving average price is $48.40 and its 200 day moving average price is $50.33. The company has a current ratio of 1.42, a quick ratio of 1.20 and a debt-to-equity ratio of 0.39.

Pfizer (NYSE:PFEGet Rating) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. The business had revenue of $27.74 billion during the quarter, compared to the consensus estimate of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The business’s revenue was up 46.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.07 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 6.54 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Stockholders of record on Friday, November 4th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.59%. Pfizer’s dividend payout ratio is currently 31.31%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on PFE shares. Barclays set a $50.00 price objective on Pfizer in a research report on Thursday, September 1st. Berenberg Bank set a $44.00 price objective on Pfizer in a research report on Wednesday, September 14th. SVB Leerink reduced their price objective on Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a research report on Friday, July 29th. UBS Group set a $59.00 price objective on Pfizer in a research report on Thursday, September 1st. Finally, JPMorgan Chase & Co. set a $57.00 price objective on Pfizer in a research report on Tuesday, June 28th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $57.00.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Articles

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.